You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Antithrombotic Therapy in Arterial and Venous Disease: Key Insights

  • Authors: Manesh R. Patel, MD; Jennifer A. Rymer, MD; David Morrow, MD, MPH; Marc P. Bonaca, MD, MPH, FAHA, FACC; Aditya Sharma, MBBS, FSVM; Geoffrey D. Barnes, MD, MSc
  • CME / ABIM MOC / CE Released: 12/30/2022
  • Valid for credit through: 12/30/2023
Start Activity

  • Credits Available

    Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.50 ABIM MOC points

    Nurses - 1.50 ANCC Contact Hour(s) (1.5 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, diabetologists and endocrinologists, primary care physicians (PCPs), nephrologists, nurses, nurse practitioners (NPs), physician assistants (PAs) and any other healthcare practitioners (HCPs) involved in the care of patients with arterial and venous disease.

The goal of this activity is that learners will be better able to review the latest advances related to antithrombotic therapy in patients with arterial and venous disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Use of antiplatelet strategies for the management of patients with acute coronary syndrome (ACS)
    • Latest data for the use of antithrombotic therapy to treat arterial and venous disease
    • Emerging reversal strategies for patients on antithrombotic therapy
  • Have greater competence related to
    • Application of evolving strategies for effective evaluation and management of coronary and venous thromboembolic disease


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Co-Chair

  • Manesh R. Patel, MD

    Chief, Division of Cardiology​
    Co-Director Duke Heart Center​
    Duke University
    Durham, North Carolina

    Disclosures

    Manesh R. Patel, MD, has the following relevant financial relationships:
    Consultant or advisor for: Bayer; Janssen; Novartis
    Research funding from: Bayer; Heartflow; Janssen; Novartis

  • Esther Kim, MD, MPH

    Director of the Center for Women’s Cardiovascular Health 
    Atrium Health Sanger Heart and Vascular Institute 
    ​Charlotte, North Carolina

    Disclosures

    Esther Kim, MD, MPH, has no relevant financial relationships.

Faculty

  • Jennifer A. Rymer, MD, MBA, MHS

    Assistant Professor of Medicine​
    Interventional Cardiology ​
    John Bush Simpson Assistant Professorship​
    Duke University Medical Center​
    Durham, North Carolina

    Disclosures

    Jennifer A. Rymer, MD, MBA, MHS, has no relevant financial relationships.

  • David Morrow, MD, MPH

    Director, Samuel A. Levine Cardiac Intensive Care Unit​
    Section Head, Critical Care Cardiology​
    Professor of Medicine​
    Harvard Medical School​
    Senior Investigator​
    TIMI Study Group, Cardiovascular Division​
    Boston, Massachusetts​

    Disclosures

    David Morrow, MD, MPH, has the following relevant financial relationships: 
    Consultant or advisor for: ARCA Biopharma; InCarda Therapeutics, Inc.; Inflammatix; Merck; Novartis; Roche Diagnostics 
    Research funding from: Abbott; Amgen, Inc.; Anthos Therapeutics; ARCA Biopharma; AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Eisai, Inc.; Merck; Novartis; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche Diagnostics; Siemens; Zora Biosciences 

  • Marc P. Bonaca, MD, MPH, FAHA, FACC

    Professor of Medicine​
    Director of Vascular Research​
    William R. Hiatt Endowed Chair in Cardiovascular Research​
    University of Colorado School of Medicine​
    Aurora, Colorado

    Disclosures

    Marc P. Bonaca, MD, MPH, FAHA, FACC, has the following relevant financial relationships: 
    Research funding from: Abbott; Agios Pharmaceuticals; Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; Amgen, Inc.; Angionetics; Anthos Therapeutics; ARCA Biopharma; Array BioPharma; AstraZeneca Pharmaceuticals LP; Atentiv; Audentes Therapeutics; Bayer; Better Therapeutics; Bristol Myers Squibb Company; Cardiol Therapeutics, Inc.; CellResearch Corporation; Cook Medical Inc.; Cook Regentec; CSL Behring; Eidos Therapeutics; EP Trading Co., Ltd.; Epizon Pharma, Inc.; Esperion Therapeutics, Inc.; Everly Well; Faraday Pharmaceuticals; Fortress Biotech, inc.; HDL Therapeutics; Heartflow; Hummingbird Bioscience; Insmed Incorporated; Janssen; Kowa Research; Lexicon Pharmaceuticals, Inc.; Medtronic, Inc.; Merck; Moderna, Inc; Novate Medical Limited; Novo Nordisk; Pfizer, Inc.; PhaseBio Pharmaceuticals, Inc.; PPD Development; Prothena Corp; Regeneron Pharmaceuticals, Inc.; Regio Biosciences; Sanifit Therapeutics S.A.; Sanofi; Silence Therapeutics; Stealth BioTherapeutics Corp; VarmX; Wraser Pharmaceuticals 
    Owns stock (publicly traded) in: Medtronic, Inc.; Pfizer, Inc. 

  • Aditya Sharma, MBBS, FSVM

    Associate Professor of Medicine​
    Medical Director, Vascular Medicine​
    Division of Cardiovascular Medicine​
    University of Virginia
    Charlottesville, Virginia

    Disclosures

    Aditya Sharma, MBBS, FSVM, has the following relevant financial relationships:
    Speaker or member of speakers bureau for: Boston Scientific (former)
    Research funding from: Vascular Medcure (former)
    Owns stock (publicly traded) in: Pfizer, Inc. (former)

  • Geoffrey D. Barnes, MD, MSc

    Professor of Medicine
    University of Michigan Frankel Cardiovascular Center
    Ann Arbor, Michigan

    Disclosures

    ​​Geoffrey Barnes, MD​, has ​the following relevant financial relationships:
    ​​Consultant or advisor for: Abbott Vascular; Acelis Connected Health; Boston Scientific; Bristol Myers Squibb Company; Janssen; Pfizer, Inc. 
    Research funding from: ​Boston Scientific​

Editor

  • Anne M. Sendaydiego, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Anne M. Sendaydiego, PharmD, has no relevant financial relationships. 

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

  • Lisa Simani, APRN, MS, ACNP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 1.50 contact hour(s) of continuing nursing education for RNs and APNs; 1.50 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Antithrombotic Therapy in Arterial and Venous Disease: Key Insights

Authors: Manesh R. Patel, MD; Jennifer A. Rymer, MD; David Morrow, MD, MPH; Marc P. Bonaca, MD, MPH, FAHA, FACC; Aditya Sharma, MBBS, FSVM; Geoffrey D. Barnes, MD, MScFaculty and Disclosures

CME / ABIM MOC / CE Released: 12/30/2022

Valid for credit through: 12/30/2023

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

  • Print